112
views
0
recommends
+1 Recommend
1 collections
    12
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model.

      Nature neuroscience
      Alzheimer Disease, complications, pathology, physiopathology, therapy, Amyloid beta-Peptides, antagonists & inhibitors, metabolism, Animals, Antibodies, Monoclonal, pharmacology, Antigen-Antibody Complex, blood, cerebrospinal fluid, Behavior, Animal, drug effects, Brain, Disease Models, Animal, Dose-Response Relationship, Drug, Immunization, Passive, Immunotherapy, Learning, Memory Disorders, Mice, Mice, Transgenic, Recognition (Psychology)

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          We have previously shown that chronic treatment with the monoclonal antibody m266, which is specific for amyloid beta-peptide (Abeta), increases plasma concentrations of Abeta and reduces Abeta burden in the PDAPP transgenic mouse model of Alzheimer's disease (AD). We now report that administration of m266 to PDAPP mice can rapidly reverse memory deficits in both an object recognition task and a holeboard learning and memory task, but without altering brain Abeta burden. We also found that an Abeta/antibody complex was present in both the plasma and the cerebrospinal fluid of m266-treated mice. Our data indicate that passive immunization with this anti-Abeta monoclonal antibody can very rapidly reverse memory impairment in certain learning and memory tasks in the PDAPP mouse model of AD, owing perhaps to enhanced peripheral clearance and (or) sequestration of a soluble brain Abeta species.

          Related collections

          Author and article information

          Comments

          Comment on this article